echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Hengrui PD-L1/TGF-βRII bifunctional fusion protein SHR-1701 was approved for clinical use

    Hengrui PD-L1/TGF-βRII bifunctional fusion protein SHR-1701 was approved for clinical use

    • Last Update: 2021-08-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 30, Hengrui issued an announcement stating that the clinical trial application of SHR-1701 injection developed by its subsidiary Shengdia was approved by the State Food and Drug Administration, specifically the comparison of SHR-1701 injection combined with axitinib tablets A multicenter, randomized, controlled, open phase Ib/III clinical study of sunitinib malate capsules for the first-line treatment of advanced renal cell carcinoma, and SHR-1701 combined with chemotherapy compared with placebo combined with chemotherapy for the treatment of advanced or untreated advanced renal cell carcinoma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.